What is the difference between somatic and germline mutations in Ovarian Cancer

Somatic vs. Germline Mutations in Ovarian Cancer

This is an important distinction that affects both your treatment options and your family's health. Let me explain the key differences:

GERMLINE MUTATIONS (Inherited)

What they are: Germline mutations are changes in your DNA that you're born with—inherited from one or both parents. These mutations are present in every cell in your body, including your egg cells (if you're a woman).

Key characteristics:

• Present from birth in all cells
• Can be passed to your children (50% chance if one parent carries it)
• Often associated with family history of cancer
• Examples: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and mismatch repair genes (MLH1, MSH2, MSH6)

Why it matters for ovarian cancer: According to NCCN Guidelines, germline BRCA1/2 mutations significantly increase ovarian cancer risk. The guidelines recommend that every patient with epithelial ovarian cancer should be referred for genetic risk evaluation and germline testing if not previously done.

---

SOMATIC MUTATIONS (Acquired)

What they are: Somatic mutations are changes in DNA that develop only in your cancer cells during your lifetime. They are NOT inherited and cannot be passed to your children.

Key characteristics:

• Develop after birth, usually due to aging or environmental factors
• Present only in the tumor tissue, not in normal cells
• Cannot be inherited
• Specific to the cancer itself
• Examples: BRCA1/2 mutations that occur only in the tumor, HER2 changes, BRAF mutations, microsatellite instability (MSI)

Why it matters for ovarian cancer: According to NCCN Guidelines, somatic tumor testing helps identify which targeted therapies might work for your specific cancer, even if you don't have an inherited mutation.

---

PRACTICAL DIFFERENCES FOR YOUR CARE

| Aspect | Germline | Somatic | |--------|----------|---------| | Testing timing | At diagnosis (recommended for all ovarian cancer patients) | At diagnosis and at recurrence | | Treatment impact | Determines eligibility for PARP inhibitors and other targeted therapies | Determines which specific drugs might work | | Family implications | Your relatives should consider genetic counseling | No family implications | | Surveillance | May affect screening for other cancers (breast, pancreatic) | Not applicable |

---

WHY BOTH MATTER FOR OVARIAN CANCER

According to NCCN Guidelines, the panel recommends:

At initial diagnosis, tumor molecular analysis should identify:

• BRCA1/2 status (germline AND somatic)
• Homologous recombination deficiency (HRD) status
• Loss of heterozygosity (LOH)

This information directly influences whether you're eligible for PARP inhibitor maintenance therapy (like olaparib or niraparib) after your first-line chemotherapy—a significant treatment advantage.

At recurrence, more comprehensive somatic testing may be recommended to identify additional treatment options, including:

• MSI/mismatch repair status
• Tumor mutational burden (TMB)
• BRAF mutations
• Other actionable mutations

---

QUESTIONS TO ASK YOUR ONCOLOGY TEAM

1. Have I been tested for germline BRCA1/2 mutations? If not, why not?
2. What were my somatic tumor test results, and what do they mean for my treatment options?
3. Do I have homologous recombination deficiency (HRD)? This affects PARP inhibitor eligibility.
4. Should my family members be tested for germline mutations? (If you have a germline mutation)
5. Will my tumor be retested if my cancer recurs? (Somatic mutations can change over time)

---

KEY TAKEAWAY

Think of it this way: Germline mutations are about YOU and YOUR FAMILY's inherited risk, while somatic mutations are about YOUR SPECIFIC CANCER and what drugs might work best against it. Both are important for making the best treatment decisions.

According to NCCN Guidelines, validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue to ensure accurate results.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.